GC Biopharma Corp.
🇰🇷South Korea
Clinical Trials
11
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:7
Phase 3:1
Not Applicable:2
Drug Approvals
1
NMPA:1
Drug Approvals
Recombinant Coagulation Factor VIII for Injection
- Product Name
- 绿茵芷
- Approval Number
- 国药准字SJ20210021
- Approval Date
- Aug 5, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (70.0%)Not Applicable
2 (20.0%)Phase 3
1 (10.0%)A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Not Applicable
Not yet recruiting
- Conditions
- Varicella (Chickenpox)Chickenpox Vaccine
- Interventions
- Biological: MG1111 (Barycela inj.)Biological: VARIVAX™
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 474
- Registration Number
- NCT07054099
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Phase 1
Recruiting
- Conditions
- Tetanus-diphtheria-acellular Pertussis (Tdap)
- Interventions
- Biological: GC3111B
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 120
- Registration Number
- NCT06997627
- Locations
- 🇰🇷
The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Phase 1
Recruiting
- Conditions
- Fabry Disesase
- Interventions
- Drug: HM15421/GC1134A
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 18
- Registration Number
- NCT06858397
- Locations
- 🇺🇸
David Geffen School of Medicine UCLA, UCLA Health, Los Angeles, California, United States
🇺🇸University of Kansas School of Medicine, Kansas City, Kansas, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Phase 1 Study of GC1130A in Pediatric Patients With Sanfilippo Syndrome Type A (MPS IIIA)
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 9
- Registration Number
- NCT06567769
- Locations
- 🇯🇵
National Center for Child Health and Development, Setagaya, Tokyo, Japan
🇺🇸UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GC2129A(Period 1)Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)Drug: GC2129A(Period 2)
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 34
- Registration Number
- NCT05729386
- Locations
- 🇰🇷
H Plus YangJi Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found